BioSpace News Archive

LogicMark , Inc. (NASDAQ: LGMK) announced today that its fourth quarter and full year 2021 financial and operating results will be released before the market opens on March 30, 2022 .

Chemomab Therapeutics Ltd. announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the fourth quarter and for the year ended December 31st, 2021, at 8:00 a.m. EDT on Monday, March 28th, 2022.

XNK Therapeutics AB announced that the first patient has been treated in a Phase II clinical study using XNK’s leading autologous natural killer cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa.

Exothera S.A., a CDMO specialized in the development and manufacture of viral vectors for vaccines and gene therapies, received Good Manufacturing Practices certification from the Federal Agency for Medicines and Health Products for its facilities in Jumet, Belgium.

CareDx, Inc. today announced that the Company won its false advertising case against Natera.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT.

Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2021.

atai Life Sciences N.V. announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update.

Rezolute, Inc. today announced positive data from its Phase 2b RIZE study of RZ358.